Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina.

ABSTRACT:

Background

Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor-ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with enalapril. It proved to be a cost-effective treatment in many countries with stable economies. In Argentina, a country with chronic financial instability and a fragmented health care system, the estimation of its cost-effectiveness requires to consider local financial data.

Objectives

To estimate the cost-effectiveness of sacubitril/valsartan in HFrEF in Argentina.

Methods

We populated an Excel-based cost-effectiveness model, previously validated, using inputs from the pivota

SUBMITTER: Giorgi MA 

PROVIDER: S-EPMC9938575 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature